
Reprogramming Cells, Decentralizing Pharma, and Understanding the Biotech Revolution.
About this episode
Francisco Gimenez is Partner at 8VC and focuses on Bio-IT investments. He received his Ph.D. from Stanford in Biomedical Informatics and B.S. in Electrical Engineering and Computer Sciences from UC Berkeley. In this episode, Francisco explains how breakthroughs in AI, gene editing, and cell therapies converged to jumpstart a new age in biology. He predicts that biomanufacturing platforms, armed with mountains of data and new tools, will bring down the costs of creating and commercializing drugs so smaller companies can treat rarer diseases and deliver more personalized cures. By decentralizing the pharma industry, Francisco is optimistic that the future of medicine will evolve from reactive care to preventative medicine that will help people fully self-actualize and lead their best, healthiest lives. [Joe is a founding partner of 8VC, his venture capital firm.]
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit blog.joelonsdale.com
Get every episode summarized
Each time Joe Lonsdale: American Optimist publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Joe Lonsdale: American Optimist

Ep 161: Generalist CEO Pete Florence on the Robot Revolution & Bringing General...
Joe Lonsdale: American Optimist

Ep 160: Box CEO Aaron Levie on Silicon Valley's AI Problem, Evidence for AI Job...
Joe Lonsdale: American Optimist

Ep 159: Aaron Cannon Is Building the Leading AI Customer Research Platform; It's...
Joe Lonsdale: American Optimist

Ep 158: Nima Ghamsari on Blend's Comeback & the Power of AI Agents and Infinite...
Joe Lonsdale: American Optimist